Biological Activity
Tavapadon (PF-06649751) is a non-catechol D1/D5 partial agonist for dopamine-receptor and motor-function research. Published human study results are separated from preclinical assays below.
In Vitro
No separate compound-specific cell or biochemical result is available from the sources summarized here.
In Vivo
No compound-specific animal efficacy result is established by the sources summarized here.
Clinical / Human Evidence
| Endpoint | Model / conditions / source | Reported result |
|---|---|---|
| Trial population | Randomized phase II study in early Parkinson disease; 57 participants, 15 weeks. [1] | 29 received PF-06649751 (tavapadon) and 28 placebo; 47 completed the study. |
| Study exposure | Once-daily oral treatment, individually titrated from 0.25 mg to a permitted maximum of 15 mg. [1] | Doses were optimized for tolerability and motor-symptom control; this describes the trial rather than a recommended regimen. |
| Motor endpoint | MDS-UPDRS part III at week 15. [1] | Mean change was −9.0 versus −4.3 with placebo; reported between-group difference 4.8 points, 90% CI 1.0–8.6, p=0.0407. |
| Adverse events and limitation | Phase II safety observations. [1] | Nausea, headache, dry mouth, somnolence and tremor were reported, mostly mild or moderate. The trial stopped enrollment early for reasons unrelated to its results. |
Interpretation
These results concern a clinical investigational formulation, not administration of the supplied research reagent.
